<br />
DERMATOLOGY<br />
EMJ Dermatol. 2019 Suppl 4 • europeanmedical-journal.com<br />
INSIDE<br />
Right Treatment<br />
to the Right Patient in<br />
Moderate-to-Severe Psoriasis:<br />
Discussion on Difference<br />
Right Treatment to the Right Patient in Moderate-<br />
to-Severe Psoriasis: Discussion on Difference<br />
This symposium took place on 11th June 2019 as part of the 24th World<br />
Congress of Dermatology (WCD) in Milan, Italy<br />
Chairpeople: Brian Kirby1<br />
Speakers: Ulrich Mrowietz,2 Lars Iversen3<br />
1. Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland<br />
2. Department of Dermatology, University Medical Center Schleswig-Holstein,<br />
Kiel, Germany<br />
3. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark<br />
Disclosure: Prof Kirby has received research grants from <a title="EMJ Dermatol. 2019 Suppl 4 page 1" href="http://viewer.zmags.com/publication/8583b33c?page=1"> DERMATOLOGY EMJ Dermatol. 2019 Suppl 4 • european</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 2" href="http://viewer.zmags.com/publication/8583b33c?page=2"> Right Treatment to the Right Patient in Moderate-</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 3" href="http://viewer.zmags.com/publication/8583b33c?page=3"> What is the Patient Perspective on Treatment Goal</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 4" href="http://viewer.zmags.com/publication/8583b33c?page=4"> to provide the long-term improvements that p</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 5" href="http://viewer.zmags.com/publication/8583b33c?page=5"> Figure 2: Cumulative ranking of novel systemic th</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 6" href="http://viewer.zmags.com/publication/8583b33c?page=6"> <65 years of age had higher expectations of their</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 7" href="http://viewer.zmags.com/publication/8583b33c?page=7"> treatment modification. As reflected in current pra</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 8" href="http://viewer.zmags.com/publication/8583b33c?page=8"> Agents Targeting IL-23 Three of the recently appr</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 9" href="http://viewer.zmags.com/publication/8583b33c?page=9"> treatment shown in clinical trials to clear the m</a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 10" href="http://viewer.zmags.com/publication/8583b33c?page=10"> of prediabetes: A prospective cohort analysis of </a>
<a title="EMJ Dermatol. 2019 Suppl 4 page 11" href="http://viewer.zmags.com/publication/8583b33c?page=11"> 54. Silva LM et al. Primary immunodeficie</a>